Addex Therapeutics Ltd. — Form SCHEDULE 13D/A
Filed September 4, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
Addex Therapeutics Ltd. filed a Schedule 13D/A amendment on September 4, 2026, signaling a change in beneficial ownership disclosure by filer Timothy Mark Dyer. The actual amendment details—including share count, percentage ownership, or transaction specifics—are not visible in the provided filing metadata and would require access to the complete document text.
Why this rating
Amendment indicates potential ownership change, but no quantitative details disclosed. Cannot assess materiality without share count, ownership %, or transaction size relative to company scale.
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.